1MAKITA N,MIYAKAWAM,FUJITATet al.Sunitinib induceshypothyroidism with a markedly reduced vascularity[].Thyroid.2010
2ROGIERS A,WOLTER P,OP DE BEECKKet al.Shrinkage ofthyroid volume in sunitinib-treated patients with renal-cell carcino-ma:a potential marker of irreversible thyroid dysfunction[].Thyroid.2010
3Rini BI,Tamaskar I,Shaheen P,et al.Hypothyroidismin pa-tients with metastatic renal cell carcinoma treated with sunitinib[].Journal of the National Cancer Institute.2007
4Motzer RJ,Hutson TE,Tomczak P,et al.Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma[].Journal of Clinical Oncology.2009
2Potapova O, Laird AD, Nannini MA, et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248[J]. Mol Cancer Ther,2006, 5(5): 1280-1289.
3The whoqol group. Development of the world health organization WHOQOL-BREF quality of life assessment[J]. Psychological Medicine, 1998, 28,551-558.
